NKTX vs NSRX

Nkarta, Inc. vs Nasus Pharma Ltd. — Valuation Comparison 2026

NKTX

Pharmaceutical Preparations
Nkarta, Inc.
Quality
4.6
out of 10
Value Trap
18
SAFE
Price
$3.25
Last close
Models
7/13
Active
VS

NSRX

Pharmaceutical Preparations
Nasus Pharma Ltd.
Quality
1.9
out of 10
Value Trap
Price
$3.36
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType NKTX Fair ValueNKTX Upside NSRX Fair ValueNSRX Upside
Bayesian DCF Intrinsic $0.54 -83.5% $0.78 -76.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $2.32 -28.5% $0.15 -95.4%
PWERM Option-Based $3.00 -7.6% $2.27 -32.4%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NKTX vs NSRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NKTX vs NSRX — Which Stock Is More Undervalued?

NKTX scores higher with a 4.6/10 quality rating vs NSRX's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Nkarta, Inc. (NKTX) and Nasus Pharma Ltd. (NSRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NKTX currently trades at $3.25 with a QOC of 4.6/10, while NSRX trades at $3.36 with a QOC of 1.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).